Latest News- Pulmonary Arterial Hypertension (PAH) Drugs Market: Oral is expected to lead the Route Of Administration segment during 2024-2028

The Pulmonary Arterial Hypertension (PAH) Drugs Market is being driven by Growing prevalence of PAH

The Pulmonary Arterial Hypertension (PAH) Drugs Market is expected to grow at a CAGR of 6.78% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 2264.7 million. The pulmonary arteries, which facilitate the transport of blood from the heart to the lungs, are afflicted by a rare and progressive disorder known as Pulmonary Arterial Hypertension (PAH). This condition is characterized by an increased pressure in these arteries due to a smaller diameter or blockages. Rising risk factors, including HIV infection, sedentary lifestyles, tobacco and alcohol consumption, and other idiopathic conditions, have led to a significant increase in the prevalence of PAH worldwide. Consequently, market participants are poised to capitalize on the expanding patient base, driving the growth of the global PAH drugs market during the forecast period. Numerous treatments are available to mitigate the progression of the disease and enhance patients' quality of life. 

Get more information on Pulmonary Arterial Hypertension (PAH) Drugs Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Route Of Administration
  • Oral
  • Injectable
  • Inhalation
• Action Mechanism
  • Prostacyclin analogs
  • Endothelin receptor antagonists (ERAs)
  • Phosphodiesterase (PDE) inhibitors
  • Soluble guanylate cyclase stimulators (SGCSs)
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Growing prevalence of PAH
• Growing geriatric population
• Increasing risk factors for cardiovascular diseases

However, the market also witnesses some limitations, which are as follows:

• High costs associated with PAH treatment
• Several side effects associated with PAH drugs
• Shortage of healthcare professionals

Benefits of Buying Global Pulmonary Arterial Hypertension (PAH) Drugs Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Pulmonary Arterial Hypertension (PAH) Drugs Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Pulmonary Arterial Hypertension (PAH) Drugs Market encompasses various treatments, including Antiproliferative Agents and Targeted Therapies. Personalized and Precision Medicine through Genetic Testing are emerging trends. Disease Progression management is crucial, along with Symptom Management and Palliative Care. Home Healthcare, Digital Health, and Patient Engagement are transforming care. Patient Advocacy, Clinical Guidelines, and Treatment Algorithms guide decision-making. Drug Safety, Adverse Events, and Drug Interactions are critical concerns. Regulatory Approval, Market Authorization, Intellectual Property, Public Health, Health Policy, and Healthcare Reform influence market dynamics. Global Health, Emerging Markets, Sustainable Healthcare, Value-Based Care, and Outcome-Based Pricing are shaping the future landscape.

Market Research Overview

The Pulmonary Arterial Hypertension (PAH) Drugs Market is a significant segment of the global pharmaceuticals industry, encompassing companies involved in the research and development (R&D) or production of both generic and non-generic drugs. According to Technavio, the global pharmaceuticals market size is determined by the collective revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of this market include the increasing global population aging, with the proportion of individuals over 60 years old in the US projected to reach 25% by 2050 and in Europe by 2030. PAH treatments, including Endothelin Receptor Antagonists, PDE5 Inhibitors, and Prostacyclin Analogs, will continue to be in high demand due to the increasing prevalence of this condition among the aging population.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/